Linda M Pilarski

Intraclonal homogeneity of clonotypic immunoglobulin M and diversity of nonclinical post-switch isotypes in multiple myeloma: insights into the evolution of the myeloma clone.

Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.

CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.

Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

The malignant clone in Waldenstrom's macroglobulinemia.

Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulimenia.

Improved resolution with microchip-based enhanced field inversion electrophoresis.

RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability.

Discussion on the safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study.

Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood.

Genetics and cytogenetics of multiple myeloma: a workshop report.

RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.

A combined dielectrophoresis, traveling wave dielectrophoresis and electrorotation microchip for the manipulation and characterization of human malignant cells.

Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.

Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity.

Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer.

Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma.

Origins of Waldenstrom's macroglobulinemia: does it arise from an unusual B-cell precursor?

Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia.

Identification of clonotypic IgH VDJ sequences in multiple myeloma.

A potential role for centrosomal deregulation within IgH translocation-positive myeloma.

Sensitive detection using microfluidics technology of single cell PCR products from high and low abundance IgH VDJ templates in multiple myeloma.

SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.

Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery.

Automated screening using microfluidic chip-based PCR and product detection to assess risk of BK virus-associated nephropathy in renal transplant recipients.

Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.

Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences.

Microfluidic chips for detecting the t(4;14) translocation and monitoring disease during treatment using reverse transcriptase-polymerase chain reaction analysis of IgH-MMSET hybrid transcripts.

Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events.

Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.

An inexpensive and portable microchip-based platform for integrated RT-PCR and capillary electrophoresis.

A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.

Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny.

Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia.

Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance.

An integrated microfluidic chip for chromosome enumeration using fluorescence in situ hybridization.

Strategies for enhancing the speed and integration of microchip genetic amplification.

The relationships among physiologic variables, quality of life, and fatigue in patients with multiple myeloma.

Genetic abnormalities in Waldenström's macroglobulinemia.

Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancer.

Promiscuity of translocation partners in multiple myeloma.

Multiple myeloma may include microvessel endothelial cells of malignant origin.

In-gel technology for PCR genotyping and pathogen detection.

In a patient with biclonal Waldenstrom macroglobulinemia only one clone expands in three-dimensional culture and includes putative cancer stem cells.

Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.

Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with Rituximab.

A miniaturized and integrated gel post platform for multiparameter PCR detection of herpes simplex viruses from raw genital swabs.

Differential positioning and close spatial proximity of translocation-prone genes in nonmalignant B-cells from multiple myeloma patients.

In multiple myeloma, bone-marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival.

In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival.

Alteration of introns in a hyaluronan synthase 1 (HAS1) minigene convert Pre-mRNA [corrected] splicing to the aberrant pattern in multiple myeloma (MM): MM patients harbor similar changes.

Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.

An enclosed in-gel PCR amplification cassette with multi-target, multi-sample detection for platform molecular diagnostics.

Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets.

The systemic cytokine environment is permanently altered in multiple myeloma.

Frequent occurrence of highly expanded but unrelated B-cell clones in patients with multiple myeloma.

Storing self-contained gel capillary cassettes for POC medical diagnostics.

A novel method for sample delivery and testing of whole blood: gel strip PCR for point of care (POC) molecular diagnostics.